- Description
- Additional
Description
Details
Description:Mouse monoclonal antibody to human Transforming Growth Factor beta (TGF-β)
Purification: Protein G affinity purified
Product Type:Primary antibody
Target Protein:Human TGF-β
Immunogen:TGF-βfrom human platelets
Fusion Myeloma: Sp2/0-Ag14
Specificity:Western blotting demonstrated that this antibody reacts with the dimeric (25 kDa) and monomeric (12.5 kDa.) forms of TGF-β under both non-reducing and reducing conditions respectively. This antibody recognizes both human platelet-derived and recombinant TGF-β in ELISA.
Species Reactivity: Human, others not tested.
Host / Isotype: Mouse, IgG1 Kappa
Formulation: Lyophilized in 0.01M PBS, pH 7.0.
Reconstitution:Double distilled water is recommended and to adjust the final concentration to 1.00 mg/mL.
Storage: Store at -20oC
Research Area:Growth Factors and Their Receptors, Angiogenesis
Background:
Transforming growth factor beta (TGF-β) has three isoforms (TGF-β1, TGF-β2, and TGF-β3) with similar functions.
The cytokine is a homodimer linked by disulfide bind. Inside cells, the cytokine forms a small latent complex with latent associated peptide (LAP). This small complex binds to latent TGF-β binding protein (LTBP) to be secreted to extra-cellular matrix. Disassociation of the latent proteins from TGF-β results in the release of the cytokine to its receptor. The process is called activation, which can be influenced by various factors, including proteases, metalloproteases, extreme pH, mild acidic condition, reactive oxygen species and integrins.
TGF-β is an anti-proliferation factor in normal cells. It increases the synthesis of p15 and p21, which can block the cyclin: CDK complex, and causes cells to stop at G1 phase. The cytokine can induce apoptosis through both SMAD and DAXX pathways. In cancer cells, TGF-β signaling is altered and TGF-β no longer stops cell proliferation.
Applications:
ELISA:The antibody reacts with TGF-β.
IHC: Can be used in immunohistochemcal applications.
Neutralizing:This antibody neutralizes TGF-β activity in vitro and in vivo.In an inhibition assay of CCL/64 cell growth and in a NRK-49F colony forming assay, the antibody neutralized TGF-β bioactivities. The effect of micro-injection of this antibody into one blastomere of two cell stage Xenopus embryos indicated that it was also able to neutralize the bioactivity of TGF-βin vivo.
References:
If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.
Additional
Additional Information
| Product Specificity | mAb anti-Human TGF-β, 8C4 |
|---|---|
| Application | EIA, IHC, NT, WB |
| Size | 0.1 mg |
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
我的邮箱：maoyuanqing@citiz.net
**捷向您推荐美国Trevigen的一款通用PARP分析试剂盒检测试剂盒。该试剂盒是检测凋亡前与凋亡中细胞提取液中PARP活性的理想方案，操作简单，重复性高。其通过检测96孔板上生物素标记的多聚ADP核糖聚合到邻近组蛋白的反应，从而确定已知的或可能的PARP抑制剂。试剂盒中的依托泊苷（Etoposide）是拓扑异构酶Ⅱ抑制剂，在拓扑异构酶Ⅱ切割完DNA后能够稳定该酶。在试剂盒中，依托泊苷作为凋亡诱导的对照参与检测。
通量PARP/凋亡分析试剂盒可广泛应用于1）检测原代、肿瘤等细胞的PARP活性；2）检测凋亡前后的PARP活性；3）利用细胞裂解液筛选PARP抑制剂。
试剂盒特色比色法/化学发光法，无放射性输出。96well，高通量检测。极大地节省了分析时间，提高了使用效率。高敏感性。能够检测到500个细胞中低至0.1mU的PARP。检测范围广。0.1-10mU。样本用量少。仅仅需要10-100ng的提取物。检测时间短。仅需要3h即可完成检测。
**捷向您提供一站式的PARP相关实验解决方案，除了高通量PARP/凋亡分析试剂盒，还有PARP体内药理动力学二代分析试剂盒(PDAII)和通用PAPR分析试剂盒外(含组蛋白包被可拆卸板)，以及相关抗体和重组蛋白。
Trevigen是一家快速成长的美国生物技术公司，专注于细胞凋亡、DNA损伤和修复、肿瘤细胞功能与行为等方面研究的肿瘤研究产品和服务。作为Trevigen在中国区域的总代理，**捷与Trevigen一道为中国的科研工作者提供最好、最新的氧化应激、细胞损伤和肿瘤细胞行为研究等领域内的优质产品和技术服务。如果您对上述产品及方案感兴趣，请致电400-6800-868至**捷科技有限公司垂询血管生成研究的相关实验解决方案，或索取最新的产品资料。
A.优点：
多重分析——一次分析可以检测16种干细胞相关的TF
定量比较——二个样本的差异可以定量分析和比较
步骤简单——探针温育、柱分离、板杂交和HRP检测
无需贵重仪器——无需如Luminex那样的贵重仪器
B.原理：
干细胞转录因子活性多重检测阵列试剂用于同时检测多种TF活性。该技术中，基于TFDNA结合位点的一致性序列，制备一系列生物素标记的探针。当探针混合物与核提取物一起温育时，每个探针寻找相应的TF，形成TF/探针复合物，通过柱离心纯化可以很容易与游离探针分开。结合的探针从混合物中分离出来，通过板杂交分析。板孔中预包被上与探针互补的特异序列，捕获的DNA探针进一步用链酶亲和素-HRP检测，化学发光检测仪测定发光强度（RLUs）。
